한글목차

반코마이신은 글리코펩티드 계열의 항균제로 경구 투여시 전신 흡수가 최소화됩니다. 이 약은 장강 내에 머무르며 대장에서 고농도로 유지됩니다. 반코마이신의 정맥 투여는 신장을 통해 배설되기 때문에 CDI 치료에서 이 제제는 대장에 도달하지 않습니다. 반코마이신은 박테리아의 세포벽 합성을 억제하며, 치료 농도에서는 정균 작용을 하는 것으로 알려져 있습니다. 이 정균 작용이 이 항균제에서 나타나는 재발의 원인이라고 생각하는 사람들도 있습니다. 반코마이신 경구 투여의 주요 장점은 약동학이 더 좋다는 것입니다. 반코마이신의 부작용으로는 복통, 복부 팽만감, 메스꺼움, 두통, 말초부종 등이 있습니다. 또한 반코마이신을 투여받는 환자는 드물게 이 치료로 인해 레드먼 증후군이 발생할 수 있다는 것을 기억하는 것이 중요합니다.

앞으로 수년간 클로스트리듐 디피실 감염증 시장 시나리오는 세계에서 광범위한 조사와 의료비 지출 증가로 인해 변화할 것입니다. 각 회사는 질병을 치료/개선하기 위한 새로운 접근 방식에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, 반코마이신의 우위에 영향을 미칠 수 있는 기회를 모색하고 있습니다. 클로스트리듐 디피실 감염에 대한 다른 신흥 제품들은 반코마이신과 치열한 시장 경쟁을 벌일 것으로 예상되며, 가까운 시일 내에 후발주자 신약이 출시되면 시장에 큰 영향을 미칠 것으로 보입니다.

주요 7개국의 반코마이신 시장에 대해 조사했으며, 시장의 개요와 2023-2032년 판매 예측 데이터, 경쟁 구도 및 국가별 동향 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 클로스트리듐 디피실 감염증에서 반코마이신의 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 규제상 마일스톤
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신규 치료법)

제5장 반코마이신 시장 평가

• 클로스트리듐 디피실 감염증에 대한 반코마이신의 시장 전망
• 주요 7개국 시장 분석
  • 주요 7개국의 클로스트리듐 디피실 감염증에 대한 반코마이신의 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

“"Vancomycin Drug Insight and Market Forecast - 2032" report provides comprehensive insights about vancomycin for clostridium difficile infection (CDI) in the seven major markets. A detailed picture of the vancomycin for clostridium difficile infection in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the vancomycin for clostridium difficile infection. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the vancomycin market forecast analysis for clostridium difficile infection in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in clostridium difficile infection.

Drug Summary:

Vancomycin is a glycopeptide antimicrobial with minimal systemic absorption when taken orally. This medication stays within the lumen of the bowel and has high concentrations in the colon. Intravenous vancomycin is excreted renally and so plays no role in the treatment of CDI as this formulation never accesses the colon. Vancomycin inhibits bacterial cell wall synthesis and, at therapeutic concentrations, this is believed to be bacteriostatic. It is this bacteriostatic effect that some believe results in the recurrences seen with this antimicrobial. The major advantage of orally administered vancomycin is its more favorable pharmacokinetics. Side effects of vancomycin include abdominal pain, flatulence, nausea, headache, and peripheral edema. It is also important to remember that patients receiving vancomycin can, rarely, develop red-man syndrome from this therapy.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the vancomycin description, mechanism of action, dosage and administration, research and development activities in clostridium difficile infection.
• Elaborated details on vancomycin regulatory milestones and other development activities have been provided in this report.
• The report also highlights the vancomycin research and development activities in clostridium difficile infection across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around vancomycin.
• The report contains forecasted sales of vancomycin for clostridium difficile infection till 2032.
• Comprehensive coverage of the late-stage emerging therapies for clostridium difficile infection.
• The report also features the SWOT analysis with analyst views for vancomycin in clostridium difficile infection.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Vancomycin Analytical Perspective by DelveInsight

In-depth Vancomycin Market Assessment

This report provides a detailed market assessment of vancomycin for clostridium difficile infection in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

Vancomycin Clinical Assessment

The report provides the clinical trials information of vancomycin for clostridium difficile infection covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for clostridium difficile infection is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence vancomycin dominance.
• Other emerging products for clostridium difficile infection are expected to give tough market competition to vancomycin and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of vancomycin in clostridium difficile infection.
• Our in-depth analysis of the forecasted sales data of vancomycin from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the vancomycin in clostridium difficile infection.

Key Questions:

• What is the product type, route of administration and mechanism of action of vancomycin?
• What is the clinical trial status of the study related to vancomycin in clostridium difficile infection and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the vancomycin development?
• What are the key designations that have been granted to vancomycin for clostridium difficile infection?
• What is the forecasted market scenario of vancomycin for clostridium difficile infection?
• What are the forecasted sales of vancomycin in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to vancomycin for clostridium difficile infection?
• Which are the late-stage emerging therapies under development for the treatment of clostridium difficile infection?

Table of Contents

1. Report Introduction

2. Vancomycin Overview in Clostridium difficile infection

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Vancomycin Market Assessment

• 5.1. Market Outlook of Vancomycin in Clostridium difficile infection
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Vancomycin in the 7MM for Clostridium difficile infection
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Vancomycin in the United States for Clostridium difficile infection
  • 5.3.2. Market Size of Vancomycin in Germany for Clostridium difficile infection
  • 5.3.3. Market Size of Vancomycin in France for Clostridium difficile infection
  • 5.3.4. Market Size of Vancomycin in Italy for Clostridium difficile infection
  • 5.3.5. Market Size of Vancomycin in Spain for Clostridium difficile infection
  • 5.3.6. Market Size of Vancomycin in the United Kingdom for Clostridium difficile infection
  • 5.3.7. Market Size of Vancomycin in Japan for Clostridium difficile infection

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options